VISTARIL (hydroxyzine pamoate) by Pfizer is clinical pharmacology hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Approved for anxiety. First approved in 1968.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
VISTARIL (hydroxyzine pamoate) is an oral anxiolytic capsule approved in 1968 for anxiety treatment. It works by suppressing activity in key subcortical CNS regions and demonstrates muscle relaxant, bronchodilator, antihistaminic, analgesic, and antiemetic properties. Clinical effects typically appear within 15-30 minutes of oral administration.
As an approaching LOE product with 30% competitive pressure, brand teams face declining revenue trajectory and likely reduced headcount allocation in coming years.
CLINICAL PHARMACOLOGY Hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the…
Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry
Worked on VISTARIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VISTARIL pamoate offers limited growth opportunity as a legacy anxiolytic approaching LOE with minimal linked job creation. Career value lies in managing a mature, high-margin franchise and executing generic transition strategy rather than building innovative pipelines.